Rebirth of the God-level Xueba

The photos on the podium had a great impact on Yang Rui.

Thalassemia major is a very serious and fatal disease, and because it is a genetic disease, it will cause terrible harm to very young children.

Pale complexion and dysplasia will appear in the first few months, followed by compensatory hyperplasia of bone marrow, which will make the bones bigger. The performance of the metacarpal bones, ribs and long bones is only one of them, but the changes of the skull will Let a one-year-old child become different. The raised forehead and cheekbones, the sunken nose, and the widened distance between the eyes will make anyone feel unbearable and uncomfortable after seeing it.

Enlarged liver and spleen and other internal organs with iron accumulation can cause internal organ damage, and externally can make the skinny child's abdomen bulge, making the whole figure look like a horrible zombie in a movie.

If it's just a photo, or an intractable disease that Yang Rui doesn't understand, it won't make Yang Rui's mood fluctuate.

However, in Yang Rui's knowledge system, although thalassemia has not been cured, it is very likely to be controlled.

Modern medicine does not have the magical power of traditional medicine. In fact, there are very few diseases that modern medicine can cure. For most diseases, the goal of modern medicine is to control rather than cure.

If the life expectancy of thalassemia major patients whose average premature death age is less than 20 years old can be increased by 10 years, or even 20 years, and their quality of life can be improved at the same time, then thalassemia major will be transformed from a terrible disease. become a terrible disease.

Among them, increasing life expectancy is only one of them, the most important thing is to improve the quality of life of patients.

Nowadays, patients with severe and moderate thalassemia need long-term blood transfusions. In order to remove the iron enrichment caused by long-term blood transfusions, they also need long-term injections of deferoxamine. Think about it, a child who is two or three years old will need What does it feel like to have frequent blood transfusions and drug injections? When other children were in kindergarten, the children with thalassemia major had been deformed all over their bodies without a piece of complete skin.

The deferiprone mentioned by Yang Rui cannot completely replace the effect of deferipramine, but it is very important that deferiprone can be taken orally and has a stronger effect. Although it cannot solve the problem of patients needing long-term blood transfusion-this requires bone marrow Transplantation - but can solve the problem of long-term injection of drugs for patients.

So, for this improvement, is it worthwhile for Yang Rui to invest in the development of thalassemia drugs?

The development of any drug is not an easy task. There are so many pharmaceutical companies in the world, how many drugs are launched in European and American countries every year? Taking the United States as a benchmark, it is usually a double-digit number below 50, and sometimes only a dozen or so.

In the U.S., where biological companies exceed 10,000, pharmaceutical companies exceed 1,000, and pharmaceutical companies all over the world want to enter the United States, only double-digit new drugs are launched every year. The difficulty of developing a new drug can be imagined.

Perhaps the development itself is not a difficult task for Yang Rui, but the first phase clinical trial, second phase clinical trial, third phase clinical trial and FDA or FDA approval is not an easy task.

Even a super pharmaceutical company like Pfizer has to peel off more than one layer of skin in a round of clinical trials for new drugs, and the painful process of peeling often lasts for three years or even ten years.

does it worth?

Intellectually speaking, Yang Rui actually believes in the importance of basic research.

For example, the drug for the treatment of thalassemia, the development of deferoxamine depends on the discovery of iron chelator, which is a natural product extracted from the fermentation broth of streptococci, and is also the result of joint research of microbiology and biochemistry. As for the deferiprone proposed by Yang Rui, as he said, it was the long-term research of carboxypyridone compounds that led to the production of related drugs.

As for Yang Rui himself, the research on the ion channel that he made in advance, and the research on the interacting protein in the laboratory, or the research on the g protein, or even the research on the cloning group that has not yet been officially operated,

Countless important medicines will be derived in varying lengths of time. Based on past experience, these important basic researches can fully influence the world for 50 or even 100 years.

It can be said that if Yang Rui focuses on basic biological research, he can create greater value, play a greater role, and lay the foundation for more people to solve their diseases.

But emotionally, Yang Rui couldn't easily convince himself.

He did not devote all his energy and time to scientific research, and even the part he devoted was not all used for basic research.

Therefore, it is not appropriate to only discuss greater value and greater effect.

Or, leave the development of deferiprone to someone else?

Yang Rui just gave up after thinking about it.

If someone else did it, then they would have to do research and development in a regular manner, that is to say, in addition to the clinical trials and drug access system for Yang Rui's headache, more energy would be spent on drug development.

When did deferiprone come into the market in history?

March 1995.

Since the discovery in 1982 that hydroxypyridone compounds are a new type of iron chelating agent with good effect, Indian pharmaceutical companies have spent another 13 years to complete the work of drug development and clinical trials.

After 13 years, how many patients with thalassemia major can wait for deferiprone?

In fact, 13 years is not enough, because deferiprone was launched in India in 1995, and it will take two or three years until it is approved by the European and American drug regulatory authorities, and it will take another five years to be launched in China, which is already accelerated. It's time.

In other words, if Yang Rui does not do it himself, but uses someone else's hands, the appearance of deferiprone will not be too early, maybe five or six years earlier, but for Chinese patients, it will still take a lifetime to wait.

Yang Rui couldn't bear it.

His thoughts were in turmoil.

does it worth? Yang Rui asked himself more than once.

If it's about benefits, it's definitely not worth it.

Deferiprone can certainly make money, but it takes so much time and energy. If it is worth the same value, Yang Rui can use the same time and energy to earn an unknown number of times the money.

But people can't just talk about interests. The reason why Yang Rui chose scientific research instead of doing business is because he didn't just talk about interests.

In terms of the balance between interests and feelings, Yang Rui usually chooses the center-left route, but this time, it seems to be the center-right position.

"I want to make this medicine." At the end of the meeting, Yang Rui suddenly said something to Xu Zhengping.

At the same time, the doctor on the stage also talked about the conclusion: "In general, Yin! Dao effervescent tablets have remarkable effects, are easy to use, have no systemic side effects when administered locally, have a definite curative effect, and can be used for a long time..."

"Let's do this, isn't it right?" Xu Zhengping was a little confused.

Wang Sisheng coughed, and said, "You don't need to speak, just put it inside."